General Announcement::Glenmark Announces Top-Line Results from Phase 3 Clinical Trial of Favipiravir

Issuer & Securities

Issuer/ Manager
GLENMARK PHARMACEUTICALS LIMITED
Securities
GLENMARK PH US$200M4.5%210802 - XS1456577334 - 4N4B
GLENMARK PHARM US$170M2%220628 - XS1426780125 - 4G8B
Stapled Security
No

Announcement Details

Announcement Title
General Announcement
Date &Time of Broadcast
22-Jul-2020 19:01:57
Status
New
Announcement Sub Title
Glenmark Announces Top-Line Results from Phase 3 Clinical Trial of Favipiravir
Announcement Reference
SG200722OTHRSCY7
Submitted By (Co./ Ind. Name)
Glenmark Pharmaceuticals Ltd.
Designation
Company Secretary & Compliance Officer
Effective Date and Time of the event
22/07/2020 00:00:00
Description (Please provide a detailed description of the event in the box below)
Glenmark Announces Top-Line Results from Phase 3 Clinical Trial of Favipiravir in Patients with Mild to Moderate COVID-19

Phase 3 Trial Demonstrates Statistically Significant Faster Time to Clinical Improvement with Favipiravir Treatment in Mild to Moderate COVID 19 Patients Compared to Control

Attachments

SGX_PR_22072020.pdf
Total size =1062K